When all patients recruited to both studies are included, novel biomarkers accurately predicted peak ALT >1000 U/l after APAP overdose. For the derivation cohort, N=28 developed ALT >1000 U/l from a total of 985. For the validation cohort N=11 developed ALT >1000 U/l from a total of 202. Biomarkers accurately predict peak ALT >1000 U/l in those patients that had a normal ALT and INR at hospital presentation. For the derivation cohort, N=18 developed ALT >1000 U/l from a total of 875. For the validation cohort N=4 developed ALT >1000 U/l from a total of 176. 
